InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Insider track record
CFODisclosed buys
1
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Chevallard Daniel R., Chief Financial Officer. Insider active across 3 companies, notably Viracta Therapeutics, Inc.. In total, 17 filings have been published. Breakdown: 1 buy · 1 sell. Total volume traded: €48k. History available since 28 May 2021. The latest transaction was filed on 14 May 2024 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations17 total
3,188 shares@ US$15.68100.0% of flowCommon StockSEC:0001815776-24-000046:0
Ideal exit: 8 Feb 2025 (T+270)
6,889 shares0Common StockSEC:0001209191-24-004037:0
6,889 shares0Common StockSEC:0001209191-23-056842:0
3,720 shares@ US$0.509.3% of flowCommon StockSEC:0001209191-23-056842:1
6,888 shares0Common StockSEC:0001209191-23-047665:0
6,889 shares0Common StockSEC:0001209191-23-032707:0
6,889 shares0Common StockSEC:0001209191-23-013854:0
6,889 shares0Common StockSEC:0001209191-22-058981:0
6,889 shares0Common StockSEC:0001209191-22-047948:0
6,889 shares0Common StockSEC:0001209191-22-032665:0
6,889 shares0Common StockSEC:0001209191-22-014438:0
13,777 shares0Common StockSEC:0001209191-21-067045:0
13,777 shares0Common StockSEC:0001209191-21-067045
10,000 shares@ US$0.9046.5% of flowCommon StockSEC:0001209191-21-058099
10,000 shares@ US$0.9046.5% of flowCommon StockSEC:0001209191-21-058099:0
12,000 shares@ US$0.9053.5% of flowCommon StockSEC:0001209191-21-036907
12,000 shares@ US$0.9053.5% of flowCommon StockSEC:0001209191-21-036907:0
17 of 17 declarations
About Chevallard Daniel R.
Daniel R. Chevallard is Chief Financial Officer and Chief Operating Officer at Viracta Therapeutics, Inc. He is responsible for the company's financial management, overseeing financial operations and strategic planning. His role is crucial in ensuring the financial health of Viracta, ensuring the company meets its financial goals while navigating a complex environment.
